Gastric microbiome dysbiosis in chronic atrophic gastritis and gastric cancer: evidence beyond Helicobacter pylori

Authors: Qin, Xiaoguang; Wang, Kaikai; Wu, Yana; Wang, Xue; Sun, Kai; Ma, Lingna; Hu, Zhihao; Wei, Huiting; Lu, Jingjing; He, Zijiao; Wang, Hongjuan; Chen, Huaixia; Li, Zhaoyu; Zhang, Haolong

Source journal: American journal of cancer research (2026-01-01)

DOI: 10.62347/UCRP1619

Abstract

Chronic atrophic gastritis (CAG) is a key precancerous condition in the multistep development of gastric cancer (GC), but the risk of malignant progression varies markedly among patients. Although Helicobacter pylori is the best-established trigger of chronic gastritis, glandular atrophy, and intestinal metaplasia, progressive hypochlorhydria, mucosal barrier impairment, and altered local immunity may also reshape the broader gastric microbiota. Apparent H. pylori-negative status should therefore be interpreted cautiously, as it may reflect previous infection, eradication, false-negative testing, low bacterial burden in advanced lesions, true never-infected status, or autoimmune AG. Enrichment of non-H. pylori taxa alone does not prove microbial replacement or H. pylori-independent causation. This review evaluates links between gastric microbiome remodeling and GC risk in CAG, focusing on microbial composition, functional pathways, mucosal immunity, oxidative stress, and epigenetic alterations. Evidence is interpreted according to disease stage, sample source, study design, and causal strength. Cross-sectional studies show stage-associated microbial differences across non-atrophic gastritis (NAG), CAG, intestinal metaplasia, dysplasia, and GC, but cannot establish temporal direction. Mechanistic data from animal, organoid, and cell models remain model-specific, whereas findings from established GC, intratumoral or fecal microbiota, metastasis, prognosis, and immunotherapy mainly reflect tumor-stage biology. Current evidence supports gastric dysbiosis as a plausible marker or context-dependent modifier, rather than an established independent driver. Prospective CAG-stage cohorts, standardized protocols, rigorous H. pylori classification, and direct functional validation are needed for clinical translation.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.